Cargando…
Hydrotalcite–Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections
COVID-19 has been affecting millions of individuals worldwide and, thus far, there is no accurate therapeutic strategy. This critical situation necessitates novel formulations for already existing, FDA approved, but poorly absorbable drug candidates, such as niclosamide (NIC), which is of great rele...
Autores principales: | Choi, Goeun, Piao, Huiyan, Rejinold, N. Sanoj, Yu, Seungjin, Kim, Ki-yeok, Jin, Geun-woo, Choy, Jin-Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160721/ https://www.ncbi.nlm.nih.gov/pubmed/34069716 http://dx.doi.org/10.3390/ph14050486 |
Ejemplares similares
-
Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy
por: Rejinold, N. Sanoj, et al.
Publicado: (2021) -
NICLOSAMIDE-EXFOLIATED ANIONIC CLAY NANOHYBRID REPURPOSED AS AN ANTIVIRAL DRUG FOR TACKLING COVID-19; ORAL FORMULATION WITH TWEEN 60/EUDRAGIT S100
por: Rejinold, N. Sanoj, et al.
Publicado: (2021) -
Niclosamide encapsulated in mesoporous silica and geopolymer: A potential oral formulation for COVID-19
por: Piao, Huiyan, et al.
Publicado: (2021) -
Niclosamide–Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment
por: Yu, Seungjin, et al.
Publicado: (2021) -
Bovine Serum Albumin-Coated Niclosamide-Zein Nanoparticles as Potential Injectable Medicine against COVID-19
por: Rejinold N, Sanoj, et al.
Publicado: (2021)